The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Fears Of South Africa Variant Raise Prospect Of Autumn Booster Jab

Mon, 08th Feb 2021 06:57

(Alliance News) - Britons face needing a third jab this year amid concerns about the Oxford University and AstraZeneca PLC vaccine's effectiveness against the South African coronavirus variant.

UK Vaccines Minister Nadhim Zahawi was forced to defend the vaccine after a new study in South Africa found it was not effective at preventing mild illness caused by the more infectious mutation.

South Africa has suspended the rollout of the British-designed vaccine to healthcare staff following the results, which have yet to be peer reviewed.

Zahawi urged the public to keep faith with the Oxford jab as scientists working on the vaccine raised the prospect of having a booster dose available by the autumn.

Writing in the Daily Telegraph, the minister said: "While it is right and necessary to prepare for the deployment of an updated vaccine, we can take confidence from the current roll out and the protection it will provide all of us against this terrible disease.

"We need to be aware that even where a vaccine has reduced efficacy in preventing infection there may still be good efficacy against severe disease, hospitalisation, and death. This is vitally important for protecting the healthcare system."

It comes as:

– The number of people in the UK who have received a first dose of a vaccine passed the 12 million mark, with jabs administered at a rate of almost 1,000 per minute during a one hour period over the weekend.

– A new Scottish record for vaccines was set, with the number of initial jabs given in one day passing 50,000 for the first time.

– Migrants living in the UK unlawfully will be given an amnesty in order to get vaccinated, the Daily Mail reported.

– People living in Northern Ireland who cross the Irish border without a reasonable excuse face a 100 euro fine from Monday.

– People who have been given both doses will be able to request their vaccine record from their GP to allow them to go on holiday to countries where immunity passports are required, Zahawi confirmed.

Scientists agreed more research is required into the level of protection the Oxford vaccine affords against the South African variant but some expressed concern over the preliminary findings from the southern hemisphere.

AstraZeneca said on Sunday the fact the study into the E484K mutation involved 2,000 people who were mostly young and healthy meant it had "not been able to properly ascertain" whether it prevented against severe illness and hospital admission.

But the Anglo-Swedish pharmaceutical company said it believed "our vaccine will still protect against severe disease" as the neutralising antibody activity is "equivalent to other Covid-19 vaccines that have demonstrated activity against more severe disease".

Sarah Gilbert, the Oxford vaccine's lead researcher, said her team was working on having an adapted version of their jab that could tackle the South Africa mutation – of which cases have been found in England – "available for the autumn".

She said: "This year we expect to show that the new version of the vaccine will generate antibodies that recognise the new variant. Then it will be very much like working on flu vaccines. It looks very much like it will be available for the autumn."

Zahawi said he and Jonathan Van-Tam, England's deputy chief medical officer, agreed there was likely to be a follow-up jab programme later in the year.

"We see very much probably an annual or booster in the autumn and then an annual (jab), in the way we do with flu vaccinations where you look at what variant of virus is spreading around the world, rapidly produce a variant of vaccine and then begin to vaccinate and protect the nation," he told BBC One's Andrew Marr Show.

The government's announcement that it had secured 20 million more rapid-result coronavirus tests signalled that the prime minister – due to set out his road map for easing restrictions later this month – could be preparing to relax lockdown rules in some settings as daily Covid deaths fell to their lowest level in weeks.

Figures showed that a further 373 people had died within 28 days of testing positive for Covid-19 as of Sunday, bringing the UK total to 112,465.

The lateral flow antigen tests, which can return results in under 30 minutes, are the first British-made tests to be validated by Public Health England in the laboratory and will be deployed to test NHS and care home staff, as well as in schools, universities, and for key workers.

But Tim Spector, professor of genetic epidemiology at King's College London, said the impact of Covid was likely to be felt at large gatherings long after lockdown was over.

He told Times Radio: "I can't see us suddenly having another Cheltenham Festival with no regulations again, I can't see us having massive weddings with people coming from all over the world.

"I think for the next few years those days are gone."

By Patrick Daly, PA Political Correspondent

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more
6 Sep 2023 07:45

AstraZeneca working with FDA on finer details of Ultomiris treatment

(Sharecast News) - Pharma giant AstraZeneca said it is "working closely" with US regulators to clarify some details of its Ultomiris drug as it hopes to bring the treatment to market as quickly as possible for people suffering from the rare disease, neuromyelitis optica spectrum disorder (NMOSD).

Read more
4 Sep 2023 15:46

UK dividends calendar - next 7 days

Tuesday 5 September 
no events scheduled 
Wednesday 6 September 
no events scheduled 
Thursday 7 September 
Admiral Group PLCex-dividend payment date
Alpha Financial Markets Consulting PLCex-dividend payment date
Anglo-Eastern Plantations PLCex-dividend payment date
Assura PLCex-dividend payment date
Athelney Trust PLCex-dividend payment date
Baltic Classifieds Group PLCex-dividend payment date
Blackrock World Mining Trust PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
CT UK Capital & Income Investment Trust PLCex-dividend payment date
Derwent London PLCex-dividend payment date
Develop North PLCex-dividend payment date
DS Smith PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Greggs PLCex-dividend payment date
Harbour Energy PLCex-dividend payment date
Pollen Street PLCex-dividend payment date
Prudential PLCex-dividend payment date
Relx PLCdividend payment date
RM Infrastructure Income PLCex-dividend payment date
Serco Group PLCex-dividend payment date
Severfield PLCex-dividend payment date
VPC Specialty Lending Investments PLCex-dividend payment date
XP Power Ltdex-dividend payment date
Zotefoams PLCex-dividend payment date
Friday 8 September 
abrdn New Dawn Investment Trust PLCdividend payment date
Avon Protection PLCdividend payment date
Berkeley Group Holdings PLCdividend payment date
Chemring Group PLCdividend payment date
Ecofin US Renewables Infrastructure Trust PLCdividend payment date
iomart Group PLCdividend payment date
Keller Group PLCdividend payment date
Lookers PLCdividend payment date
Moneysupermarket.com Group PLCdividend payment date
Nichols PLCdividend payment date
Tritax EuroBox PLCdividend payment date
Tyman PLCdividend payment date
Monday 11 September 
AstraZeneca PLCdividend payment date
Games Workshop Group PLCdividend payment date
Rentokil Initial PLCdividend payment date
Residential Secure Income PLCdividend payment date
ThomasLloyd Energy Impact Trust PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more
29 Aug 2023 12:33

US government names first 10 drugs for Medicare price negotiation

Aug 29 (Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.

Read more
29 Aug 2023 11:00

US to name first 10 drugs for Medicare price negotiation

Aug 29(Reuters) - The Biden administration on Tuesday is expected to release its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people.

Read more
25 Aug 2023 11:59

Novo says Wegovy drug helps obese people with heart failure in trial

Aug 25 (Reuters) - Novo Nordisk said its hugely popular drug Wegovy was shown to substantially ease heart failure in obese people, as the Danish drugmaker seeks to further build its case for the medicine's health benefits beyond weight loss.

Read more
24 Aug 2023 16:24

UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan.

Read more
24 Aug 2023 08:25

AstraZeneca says Soliris and Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC on Thursday said both its Soliris and Lynparza treatments have been approved in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.